BioSpace News Archive

- Titan today announced that it has entered into a definitive asset purchase agreement (the “Agreement”) with JT Pharmaceuticals, Inc.

ENDRA Life Sciences Inc. announces it has been issued European Patent EP 3 294 142 B1 (the ‘142 patent) from the European Patent Office

NeuroEM Therapeutics is poised to deliver a knockout blow to Alzheimer’s disease. The clinical-stage medical device company is pleased to announce FDA Breakthrough Device designation for its bioengineered head device shown to reverse Alzheimer’s memory loss in its pilot study, published last fall in the Journal of Alzheimer’s Disease.

Synergis Software, a global leader in engineering information management and product data management (PDM), today announced that its flagship product, Adept, has earned 21 top placements in G2 Crowd’s Fall 2020 Grid Reports.

Yield10 Bioscience, Inc., an agricultural bioscience company, announced that it has begun field testing to evaluate the emergence and agronomics of winter Camelina sativa varieties.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA), and Longboard Pharmaceuticals, Inc., today announced the launch of Longboard Pharmaceuticals and the completion of a $56 million financing led by Farallon Capital Management, LLC, and other top tier healthcare investors,

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4th.

Dental Professionals Providing Patients with Superior Aligners and Individualized Guidance at a Competitive Price Point

Applied UV, Inc., an infection prevention technology company that applies the power of ultra violet C light utilizing its patented devices to destroy pathogens safely, thoroughly, and automatically, announced that its subsidiary, SteriLumen, Inc., and Axis Lighting, Inc. of Quebec, Canada, have entered into an exclusive license and joint development agreement.

Stream Biomedical, Inc., a privately-held company developing novel therapeutics for the treatment of acute stroke and Alzheimer’s disease, announced today that William D. Schwieterman, M.D. has been appointed as Chief Executive Officer. Gary B. Gage, PE, MBA, the company’s founder, continues as Chief Operating Officer.